Literature DB >> 6428589

Antiemetic prophylaxis with high dose metoclopramide or lorazepam in vomiting induced by chemotherapy.

S J Bowcock, A D Stockdale, J A Bolton, A A Kang, S Retsas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6428589      PMCID： PMC1441757          DOI： 10.1136/bmj.288.6434.1879

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  3 in total

1.  Intravenous lorazepam to prevent nausea and vomiting associated with cancer chemotherapy.

Authors:  J Maher
Journal:  Lancet       Date:  1981-01-10       Impact factor: 79.321

2.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

3.  Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.

Authors:  R J Gralla; L M Itri; S E Pisko; A E Squillante; D P Kelsen; D W Braun; L A Bordin; T J Braun; C W Young
Journal:  N Engl J Med       Date:  1981-10-15       Impact factor: 91.245
  3 in total
  3 in total

Review 1.  Pharmacological Agents Affecting Emesis : A Review (Part II).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

2.  Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review.

Authors:  Albert Tuca
Journal:  Cancer Manag Res       Date:  2009-12-16       Impact factor: 3.989

3.  The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial.

Authors:  M E O'Brien; M H Cullen; C Woodroffe; K Kelly; C Burman; K Palmer; N S Stuart; G R Blackledge; J Sharpe
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.